[11C]Harmine Binding to Brain Monoamine Oxidase A: Test-Retest Properties and Noninvasive Quantification
- PMID: 29423903
- DOI: 10.1007/s11307-018-1165-3
[11C]Harmine Binding to Brain Monoamine Oxidase A: Test-Retest Properties and Noninvasive Quantification
Abstract
Purpose: Inhibition of the isoform A of monoamine oxidase (MAO-A), a mitochondrial enzyme catalyzing deamination of monoamine neurotransmitters, is useful in treatment of depression and anxiety disorders. [11C]harmine, a MAO-A PET radioligand, has been used to study mood disorders and antidepressant treatment. However, [11C]harmine binding test-retest characteristics have to date only been partially investigated. Furthermore, since MAO-A is ubiquitously expressed, no reference region is available, thus requiring arterial blood sampling during PET scanning. Here, we investigate [11C]harmine binding measurements test-retest properties; assess effects of using a minimally invasive input function estimation on binding quantification and repeatability; and explore binding potentials estimation using a reference region-free approach.
Procedures: Quantification of [11C]harmine distribution volume (VT) via kinetic models and graphical analyses was compared based on absolute test-retest percent difference (TRPD), intraclass correlation coefficient (ICC), and identifiability. The optimal procedure was also used with a simultaneously estimated input function in place of the measured curve. Lastly, an approach for binding potentials quantification in absence of a reference region was evaluated.
Results: [11C]harmine VT estimates quantified using arterial blood and kinetic modeling showed average absolute TRPD values of 7.7 to 15.6 %, and ICC values between 0.56 and 0.86, across brain regions. Using simultaneous estimation (SIME) of input function resulted in VT estimates close to those obtained using arterial input function (r = 0.951, slope = 1.073, intercept = - 1.037), with numerically but not statistically higher test-retest difference (range 16.6 to 22.0 %), but with overall poor ICC values, between 0.30 and 0.57.
Conclusions: Prospective studies using [11C]harmine are possible given its test-retest repeatability when binding is quantified using arterial blood. Results with SIME of input function show potential for simplifying data acquisition by replacing arterial catheterization with one arterial blood sample at 20 min post-injection. Estimation of [11C]harmine binding potentials remains a challenge that warrants further investigation.
Keywords: Brain; Monoamine oxidase A; Noninvasive estimation; Positron emission tomography; Repeatability.
Similar articles
-
Positron emission tomography quantification of [11C]-harmine binding to monoamine oxidase-A in the human brain.J Cereb Blood Flow Metab. 2006 Mar;26(3):330-44. doi: 10.1038/sj.jcbfm.9600197. J Cereb Blood Flow Metab. 2006. PMID: 16079787
-
Monoamine oxidase A inhibitor occupancy during treatment of major depressive episodes with moclobemide or St. John's wort: an [11C]-harmine PET study.J Psychiatry Neurosci. 2011 Nov;36(6):375-82. doi: 10.1503/jpn.100117. J Psychiatry Neurosci. 2011. PMID: 21463543 Free PMC article. Clinical Trial.
-
Imaging of monoamine oxidase-A in the human brain with [11C]befloxatone: quantification strategies and correlation with mRNA transcription maps.Nucl Med Commun. 2014 Dec;35(12):1254-61. doi: 10.1097/MNM.0000000000000196. Nucl Med Commun. 2014. PMID: 25185897 Clinical Trial.
-
Radiochemistry devoted to the production of monoamine oxidase (MAO-A and MAO-B) ligands for brain imaging with positron emission tomography.J Labelled Comp Radiopharm. 2013 Mar-Apr;56(3-4):78-88. doi: 10.1002/jlcr.3007. J Labelled Comp Radiopharm. 2013. PMID: 24285313 Review.
-
Non-invasive kinetic modelling approaches for quantitative analysis of brain PET studies.Eur J Nucl Med Mol Imaging. 2023 May;50(6):1636-1650. doi: 10.1007/s00259-022-06057-4. Epub 2023 Jan 18. Eur J Nucl Med Mol Imaging. 2023. PMID: 36651951 Free PMC article.
Cited by
-
Monoamine Oxidase Inhibitors: From Classic to New Clinical Approaches.Handb Exp Pharmacol. 2021;264:229-259. doi: 10.1007/164_2020_384. Handb Exp Pharmacol. 2021. PMID: 32852645 Review.
-
Towards Imaging Tau Hyperphosphorylation: Is DYRK1A a Potential Target for Imaging Hyperphosphorylation of Tau? Molecular Modeling Assessment and Synthesis of [125I]Radioiodinated DYRK1A Inhibitor.Molecules. 2025 Feb 21;30(5):990. doi: 10.3390/molecules30050990. Molecules. 2025. PMID: 40076215 Free PMC article.
-
Elevated Monoamine Oxidase-A in Anterior Cingulate of Post-Mortem Human Parkinson's Disease: A Potential Surrogate Biomarker for Lewy Bodies?Cells. 2022 Dec 10;11(24):4000. doi: 10.3390/cells11244000. Cells. 2022. PMID: 36552764 Free PMC article.
-
Radiosynthesis, Preclinical, and Clinical Positron Emission Tomography Studies of Carbon-11 Labeled Endogenous and Natural Exogenous Compounds.Chem Rev. 2023 Jan 11;123(1):105-229. doi: 10.1021/acs.chemrev.2c00398. Epub 2022 Nov 18. Chem Rev. 2023. PMID: 36399832 Free PMC article. Review.
-
Comparison of Monoamine Oxidase-A, Aβ Plaques, Tau, and Translocator Protein Levels in Postmortem Human Alzheimer's Disease Brain.Int J Mol Sci. 2023 Jun 28;24(13):10808. doi: 10.3390/ijms241310808. Int J Mol Sci. 2023. PMID: 37445985 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources